Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ethyl eicosapentaenoic acid - Amarin

Next Previous
Drug Profile

Ethyl eicosapentaenoic acid - Amarin

Alternative Names: VAZKEPA; AMR-101; Eicosapentaenoic acid ethyl ester - Amarin; Eicosapentanoic acid ethyl ester; EPA-Vascepa; Ethyl eicosapentaenoate; Ethyl eicosopentaenoate; Ethyl icopenate; Ethyl-EPA; Icosapent ethyl - Amarin Corporation; Icosapentaenoic acid ethyl ester; LAX-101; LAX-101c; Miraxion™; Ultra-pure eicosapentaenoic acid; Ultra-pure EPA; Ultra-pure ethyl ecosapentaenoic acid; Ultra-pure ethyl EPA; Vascepa; VAZKEPA; Vazkepa

Latest Information Update: 23 Dec 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Scarista
  • Developer Amarin Corporation; Biologix FZCo; Eddingpharm; HLS Therapeutics; University of Leeds; Yorkshire Cancer Research
  • Class Antidementias; Antidepressants; Antihyperlipidaemics; Antineoplastics; Antiplatelets; Antivirals; Eicosanoids; Esters; Omega 3 fatty acids; Reactive oxygen species; Small molecules; Vascular disorder therapies
  • Mechanism of Action Diacylglycerol O-acyltransferase inhibitors; Phospholipase A2 inhibitors; Platelet aggregation inhibitors; Triglyceride modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Huntington's disease
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Hyperlipidaemia; Hypertriglyceridaemia
  • Registered Cardiovascular disorders
  • Phase III Colorectal cancer; COVID 2019 infections; Liver metastases
  • Discontinued Huntington's disease; Major depressive disorder; Memory disorders; Parkinson's disease; Psychotic disorders

Most Recent Events

  • 29 Aug 2025 Efficacy data from the phase III REDUCE-IT trial in Hypertriglyceridaemia presented at the ESC Congress 2025 - Annual Congress of the European Society of Cardiology together with World Congress of Cardiology (ESC-Card-WCC-2025)
  • 24 Jun 2025 Ethyl eicosapentaenoic acid licensed to Recordati for commercialization in Europrean Union
  • 31 Mar 2025 Pharmacodynamics data from a preclinical trial in Cardiovascular disorders released by Amarin Corporation

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top